Find Reports
Select Report Type
Reimbursement Review
Displaying 401 - 425 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | PC0151-000 | |||
| Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0574-000 | |||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | SR0577-000 | |||
| Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0594-000 | |||
| Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | SR0586-000 | |||
| Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0581-000 | |||
| Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0582-000 | |||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | PC0152-000 | |||
| Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | PC0131-000 | |||
| Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0150-000 | |||
| Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0146-000 | |||
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | PC0138-000 | |||
| Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0591-000 | |||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0592-000 | |||
| Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0593-000 | |||
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | SR0570-000 | |||
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SR0573-000 | |||
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0149-000 | |||
| Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | PC0154-000 | |||
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | PC0147-000 | |||
| Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | PC0145-000 | |||
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0572-000 | |||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | SR0576-000 | |||
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0163-000 | |||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | SR0565-000 |
Health Technology Review
Displaying 401 - 425 of 589
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 401 - 425 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Dapagliflozin | Reimbursement Review | Complete | SR0428-000 | ||||
| Linagliptin-metformin | Reimbursement Review | Complete | SR0306-000 | ||||
| Saxagliptin | Reimbursement Review | Complete | SR0329-000 | ||||
| Saxagliptin + Metformin | Reimbursement Review | Complete | SR0348-000 | ||||
| Canagliflozin | Reimbursement Review | Complete | SR0370-000 | ||||
| Empagliflozin and metformin | Reimbursement Review | Complete | SR0489-000 | ||||
| Sitagliptin phosphate | Reimbursement Review | Complete | SR0181-000 | ||||
| Sitagliptin phosphate monohydrate / metformin hydrochloride | Reimbursement Review | Complete | SR0182-000 | ||||
| Linagliptin | Reimbursement Review | Complete | SR0244-000 | ||||
| Colorectal cancer | Reimbursement Review | Provisional Funding Algorithm | Withdrawn | PH0043-000 | |||
| Chronic Lymphocytic Leukemia | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0038 -000 | |||
| risperidone | Reimbursement Review | Suspended | SR0811-000 | ||||
| Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease | This Environmental Scan assesses the current reimbursement of the SGLT2 drug class relevant to public drug programs, including the regulatory, exclusivity, reimbursement review, and reimbursement status of these drugs for type 2 diabetes mellitus, heart failure, and chronic kidney disease. | Horizon Scan | Environmental Scan | Completed | ES0370-000 | ||
| NovoTTF-200A | Health Technology Review | Optimal Use | Completed | OP0554-000 | |||
| Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis | Health Technology Review | Observational Study | Complete | OS0003-000 | |||
| Reprocessed Single-Use Semicritical and Critical Medical Devices | We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs. | Health Technology Review | Rapid Review | Completed | RC1511-000 | ||
| upadacitinib | Reimbursement Review | Complete | SR0775-000 | ||||
| Aerosol Therapy With Inhalers During Mechanical Ventilation | Health Technology Review | Rapid Review | Completed | RC1529-000 | |||
| Pan- Canadian Rare Disease Registries | Health Technology Review | Environmental Scan | Completed | ES0369-000 | |||
| andexanet alfa | Reimbursement Review | Complete | ST0772-000 | ||||
| Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus | Reimbursement Review | Streamlined Drug Class Review | Complete | TS0002-000 | |||
| Ketamine for Adults With Substance Use Disorders | To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs. | Health Technology Review | Rapid Review | Completed | RC1523-000 | ||
| Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle | Health Technology Review | Rapid Review | Completed | RC1528-000 | |||
| Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery | Health Technology Review | Rapid Review | Completed | RC1530-000 | |||
| 2024 Watch List: Care for Children and Youth With Medical Complexity | The 2024 Watch List aims to identify and describe technologies and issues related to the care of children and youth with medical complexity that are likely to affect health care delivery and planning in Canada in the next 5 years. |
Horizon Scan | Roundup | Completed | ER0014-000 |